09.07.2022 |
Preclinical safety and toxicokinetics of VMX-C001 – an intravenous bypassing agent for factor Xa inhibitors
VMX-C001, a modified form of human zymogen factor X, is being developed to stop or prevent bleeding in patients taking factor Xa inhibitors and is currently in human phase I studies.
Related items
24.06.2023
Factor Xa direct oral anticoagulants (Fxa-DOACs) require rapid reversal in patients with serious bleeding or prior to urgent surgery.
09.07.2022
VMX-C001, a modified form of human zymogen factor X, is being developed to stop or prevent bleeding in patients taking…